Anzeige
Mehr »
Freitag, 13.02.2026 - Börsentäglich über 12.000 News
Top-Ergebnisse: 1,75 g/t Gold über 30,4 Meter + massives Tagebau-Potenzial
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
43 Leser
Artikel bewerten:
(0)

Congress of Racial Equality (CORE) Alerts Black and Hispanic Congressional Caucus Reported Walgreens Prescription Drug Changes Will Hurt the Poor

NEW YORK, Dec. 20, 2011 /PRNewswire-USNewswire/ -- The Congress of Racial Equality, a 70-year-old civil rights organization, sent a letter to the entire Black and Hispanic Congressional delegation alerting Congress of the dangers of Walgreens' widely publicized threat to end their partnership with Express Scripts at the end of the year.

Many working class Americans of color depend on the discounted prescription rates they are able to secure through the partnership.

National Spokesman Niger Innis warned the Congressmen that their constituents could face up to a 30% increase in the cost of vital medication should Walgreens no longer honor Express Scripts prescriptions. According to a story in AP, 1 out of 2 Americans are now living in or near poverty. This record number of Americans is largely due to the rise in the cost of living.

"At a time when record numbers of Americans find themselves barely scraping by to survive, the last thing Walgreens needs to do is end a partnership that helps millions of Americans of color," Innis said.

December 20, 2011

Dear Member of Congress:

On behalf of the Congress of Racial Equality (CORE), I am writing to express the concern we have with the probable end of the partnership between Walgreens and Express Scripts. Many working class Americans of color depend on the discounted prescription rates they are able to secure through Express Scripts.

Many within the business community and business media estimate vulnerable populations could face up to a 20% increase in prices for vital medication. In a weak economy that has hit the minority community particularly hard, that increase will harm the health of countless people and could essentially be a death sentence for many.

They also assert this decision of Walgreen's is going to hurt Walgreen's bottom line profits. CORE is troubled by the assertion of some that should the above stated presumptions (profit loss for Walgreen's and working class patients increased costs); the only motivation Walgreen's could have in making this decision is a desire to minimize or eliminate lower income customers.

Considering Walgreen's recent history and image, and the importance and difficulties with health care access that already exists in low-income communities, we strongly urge you to ask them to reconsider this decision.

In the past few years Walgreens hasbeen sued by several states for allegedly eliminating or restricting access for Medicaid patients; this alleged practice may have led to the death of a child in Denver who was subject to inferior care due to a Medicaid coverage dispute. Walgreens was also sued by the Bush administration's EEOC for alleged illegal discriminatory employment practices against 10,000 African American pharmaceutical (and other) employees.

This decision to terminate the partnership with Express Scripts, and the unintended consequences visited on vulnerable patients, would add to a disturbing narrative about the Walgreen's corporation. We seek your voice in strongly urging they reconsider this dangerous decision.

Niger Innis
National Spokesman
CORE

SOURCE Congress of Racial Equality (CORE)

© 2011 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.